
About Voxtur Bio
Voxtur Bio is a Healthcare company based in Thane (India) founded in 2013. Kits and reagents for in vitro diagnostics are developed. Voxtur Bio has raised $3.16 million across 3 funding rounds from investors including Acumen Group, Ganesh Srinivasan and Equity Intelligence. The company has 14 employees. Voxtur Bio was last valued at $29.69 million in November 2019. Its Indian entity Voxtur Bio Limited reported revenue of βΉ51.38 Cr. Voxtur Bio offers products and services including VoxPress HIV 1 & 2 Rapid Card Test, VoxPress HCV Rapid Card Test, VoxSera Anti-A, VoxSera Anti-B, and VoxBank Widal 8 Antigen Slide Set. Its focus areas include Life Sciences, Infectious Diseases, In Vitro Diagnostic Tests and Viral.
Company details
Voxtur Bio was founded in 2013 and is based in Thane, India. Operations focus on the in vitro diagnostics sector, where kits and reagents are developed for clinical use. VoxPress and VoxEl product lines are utilized as point-of-care and clinical immunoassays targeting infectious diseases, including HIV, HCV, toxoplasma, rubella, herpes, and CMV. Consumables and additional reagents for diagnostics are also produced.
- Headquarters Thane, India
- Employees 14
- Stage Minicorn
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Website voxturbio.com
- Social LinkedIn Facebook Instagram
- Legal Name Voxtur Bio Limited
- Date of Incorporation 06 Dec, 2012
- Jurisdiction Vasai, Maharashtra, India
- Annual Revenue₹51.38 Cr
FY 2024 · +38% YoY
- Net Profit₹4.55 Cr
FY 2024 · 9% margin
- EBITDA₹9.95 Cr
FY 2024 · 19% margin
- Total Equity Funding$3.16M (USD)
in 3 rounds
- Latest Funding Round$1.6M (USD), Angel Round
Nov 2019
- InvestorsAcumen Group
& 31 more
- Employee Count14
Associated legal entities of Voxtur Bio
Voxtur Bio operates through Voxtur Bio Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2024) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Voxtur Bio Limited CIN U25190MH2012PLC238544 | Active | 06 Dec 2012 | Vasai, Maharashtra | ₹51.4 Cr | 14 | 4 | View details |
Products & Services of Voxtur Bio
Voxtur Bio offers a comprehensive portfolio of products and services, including VoxPress HIV 1 & 2 Rapid Card Test, VoxPress HCV Rapid Card Test, VoxSera Anti-A, VoxSera Anti-B, and VoxBank Widal 8 Antigen Slide Set.
Rapid test for detecting HIV 1 and 2 infections.
Test for Hepatitis C virus detection.
Reagent for identifying blood type Anti-A.
Reagent for identifying blood type Anti-B.
Slide set for typhoid fever antigen testing.
Funding Insights of Voxtur Bio
Voxtur Bio has successfully raised a total of $3.16M across 3 strategic funding rounds. The most recent funding activity was a Angel Round of $1.6 million completed in November 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $3.16M
- Total Rounds 3
- Last Round Angel Round β $1.6M
- First Round $413,800
(May 2016)
- Investors Count 32
All 3 funding rounds of Voxtur Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2019 | $1.6M | Angel Round | $29.69M | Ganesh Srinivasan | β |
| Feb 2017 | $1.15M | Seed | $9.39M | Equity Intelligence, Ganesh Srinivasan | |
| May 2016 | $413,800 | Angel Round | $β’β’β’β’β’ | Hiren Shantilal Batavia |
| Date | Valuation | Stage |
|---|---|---|
| Nov 2019 | $29.69M | β’β’β’β’β’β’β’β’ |
| Feb 2017 | $9.39M | β’β’β’β’β’β’β’β’ |
| May 2016 | $β’β’β’β’β’ | β’β’β’β’β’β’β’β’ |
Full valuation and stage history of Voxtur Bio
Every valuation point, the growth-stage changes (minicorn, soonicorn, unicorn) and the dates behind them require an active premium plan.
- All valuation points
- Stage changes
- Dates
- Exports
Verified entity values are shown only after access is granted.
Last known valuation $29.69M (Nov 2019). 32 investors in total: 3 institutional and 29 angel.
Investors in Voxtur Bio
Voxtur Bio has secured backing from 32 investors, including angel, venture fund, and institutional investors. Prominent investors backing the company include Acumen Group, Ganesh Srinivasan and Equity Intelligence.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Multiple sectors are invested in by the private equity fund. | equityintelligence.com | Kochi, India | ||
Online platform offering technical analysis solutions | 2008 | acumengroup.in | Kochi, India | |
NovoMed is engaged in distributing advanced medical devices. | novomed.in | Mumbai, India | ||
GS Ganesh Srinivasan | Angel investor, ex-Amazon and Flipkart leader, focused on tech startups | unknown_2187c616cad14fc39 | ||
MS Maheshwari Shrigopal Sunil | unknown_5161e6eb08fb4745b | |||
DC Debashree Choudhary Chakraborty | unknown_317edcc7acba4eb9b | |||
LS Leela Sunil Maheshwari | unknown_18c7191f68a2426f8 | |||
AS Anil Sarin | Angel investor, Chief Growth Officer at WhiteHat Jr, ex-Ola executive | unknown_bf724386df6d448da | ||
AC Anik Chandrakant Shah | unknown_e7ecd7a645524ae99 | |||
MK Manish Kumar Jain | Angel investor, tech entrepreneur, and advisor in Indian startup ecosystem | unknown_9d369248e31149ec8 |
Investor details for Voxtur Bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Voxtur Bio Limited (Voxtur Bio)
Voxtur Bio Limited is the primary company behind Voxtur Bio. The board of Voxtur Bio Limited currently have 3 directors; the longest-serving is Veeraal Ramesh Gandhi, appointed in 2012. 12 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Veeraal Ramesh Gandhi DIN 01450653 | Managing Director | 06 Dec 2012 | 13 yrs 11 mo | Voxtur Bio Limited |
| Nikhil Dilipbhai Bhuta DIN 02111646 | Director | 01 Dec 2022 | 3 yrs 11 mo | Voxtur Bio Limited |
| Rajasekharan Bhaskaran Nair DIN 00655414 | CFO | 25 Sep 2024 | 2 yrs 1 mo | Voxtur Bio Limited |
Financials of Voxtur Bio
Figures of Voxtur Bio Limited, the primary company behind Voxtur Bio, for FY 2024. Revenue was ₹51.38 Cr (+38% year on year). Net profit was ₹4.55 Cr (9% margin). EBITDA was ₹9.95 Cr (19% margin). Revenue has grown at a compounded annual rate of +11% over three years and +25% over five years.
- ₹51.38 CrRevenue · FY 2024 · +38% YoY
- ₹4.55 CrNet profit · 9% margin
- ₹9.95 CrEBITDA · 19% margin
- ₹6.37 CrPaid-up capital
- 14Employees (provident fund records)
- +11%Revenue CAGR, 3 years
- +25%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Voxtur Bio Limited are on its company page.
Detailed financial statements for Voxtur Bio
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Voxtur Bio
4 dated milestones of Voxtur Bio across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Voxtur Bio is founded.
- Funding First funding round of $414K.
- Milestone Reaches Minicorn status.
- Funding Latest funding round, Angel Round, of $1.6M.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Voxtur Bio
Complete news archive for Voxtur Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Voxtur Bio
Voxtur Bio was founded in 2013 and raised its 1st funding round 3 years after it was founded.
Voxtur Bio is headquartered in Thane, India. It is registered at Thane, Maharashtra, India.
Voxtur Bio is a funded company, having raised a total of $3.16M across 3 funding rounds to date. The company's 1st funding round was a Angel Round of $413.8K, raised on May 2016.
Voxtur Bio has 14 employees.
The primary company behind Voxtur Bio, Voxtur Bio Limited, reported revenue of βΉ51.38 Cr for FY 2024, up 38% year on year.
Voxtur Bio was founded in 2013 and is based in Thane, India. Operations focus on the in vitro diagnostics sector, where kits and reagents are developed for clinical use. VoxPress and VoxEl product lines are utilized as point-of-care and clinical immunoassays targeting infectious diseases, including HIV, HCV, toxoplasma, rubella, herpes, and CMV. Consumables and additional reagents for diagnostics are also produced.
Voxtur Bio offers VoxPress HIV 1 & 2 Rapid Card Test, VoxPress HCV Rapid Card Test, VoxSera Anti-A, VoxSera Anti-B, and VoxBank Widal 8 Antigen Slide Set.
Voxtur Bio has 32 investors. Key investors include Acumen Group, Ganesh Srinivasan, Equity Intelligence, Maheshwari Shrigopal Sunil, and Debashree Choudhary Chakraborty.
The valuation of Voxtur Bio is $29.69M as of Nov 2019.
Voxtur Bio operates through Voxtur Bio Limited.
The legal entities of Voxtur Bio currently have 4 directors, including Nikhil Dilipbhai Bhuta, Veeraal Ramesh Gandhi, Rajasekharan Bhaskaran Nair and others.
